Knight Therapeutics Inc T.GUD

Bring back Beaudet

[PitchinPennies]

Possibly I'm wrong, but my retrospective thought is that Marc Beaudet, co-founder with Goodman of Paladin Labs, was the essential ingredient in the previous company's success. Not having Beaudet as a sparkplug, or wingman, or comedy partner, means you need to deduct at least 35 of Goodman's famous IQ points, and therein lies the recent problem. If Beaudet had been around, would he have talked Goodman out of some of the non-accretive and/or really stupid deals of the past five years (Medison, etc.)? I do wonder.

A simple solution would be to put the band back together. Beaudet and Goodman were the Lennon and McCartney of pharma. Samira's a perfectly fine executive, but, to continue the analogy, she's more of a pleasant opening act, like Mary Hopkins.

[EbbFlow88]

Maybe, but it's still too early to tell. So far the company is progressing well in regards to cash generation and seems to be on a solid tragectory. I also think Samira has and wants to prove everyone wrong. This story just needs time. 

[Chianchin]

Eight Years too early? From $10.50 to $5.50 shareprice. I say tool ate? 

[longrun86]

It's a small world out there and people always go to those they confide in and trust. Perhaps Goodman did have discussions with his trusted network on things. I think it's early yet to judge the impact Samira has and will have on Knight. Covid no doubt delayed the integration of Biotiscana which pushed back or delayed the return trajectory of that acquisition. Knight is due for a

[Chianchin]

I agee, being very busy losing money and market cap for eight long years and now overpaying for share buyback. The original long term holders need $15 just to break even. Alas, they get all pumped up when GUD goes up by $.03.